Endocrine Abstracts

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the MEN1 gene (a tumor supressor gene) leading to the development of endocrine and non-endocrine tumours with variable penetrance.The most frequent features are primary hyperparathyroidism, duodeno pancreatic endocrine tumours and pituitary adenomas.Aim of the work: The aim of this retrospective study was to establish the pre...

Introduction: The true prevalence of clinically relevant pituitary adenomas has been reevaluated at 1/1064 of the population (1). Among them, prolactinomas represent the majority with a prevalence of 1/2000. They occur usually in females, aged 20–50 Y.O., and 80% are microadenomas. Nearly 5% of prolactinomas appear in a familial or genetic setting (MEN-1 or FIPA) (2). Cabergoline is proposed as the first line therapy and is usually efficient to normalize prolactin (PRL) l...

Immune checkpoints inhibitors have fundamentally changed the management of oncologic patients. These treatments consist of monoclonal antibodies directed against CTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (programmed cell death protein-1) and PD-L1 (one of its ligands). By blocking these receptors or ligands, the antibodies reverse the immune tolerance induced by the cancerous cell on the T-lymphocyte and favour lymphocytic reactivation and anti-tumor activity. Immune tol...

Aim of the work: Clinical research studies over the last 15 years have reported a significant burden of hypopituitarism in survivors of traumatic brain injury (TBI). However, these endocrine anomalies remain under diagnosed due to nonspecific clinical signs and misunderstanding of the phenomenon. The aim of the work is to evaluate for the first time in Belgium their prevalence and to quantify the deficits of the different pituitary axes in patients recruited to the endocrinolo...

Introduction: Drospirenone is a synthetic progestin usually found in combination with ethynilestradiol in oral contraceptive formulas. In 2007, this compound was also used in hormonal replacement therapy during menopause. Drospirenone shows antimineralocoricoïd effect due to an analogy of structure with aldosterone. This effect counteracts the estrogen stimulating action of renin–angiotensin–aldosterone (RAA) system, lowering water retention symptoms due to clas...